Clinical Trials
48 trialsExploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
National Institutes of Health Clinical Center (CC)
Rare CNS Tumors Outcomes &Risk
National Institutes of Health Clinical Center (CC)
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Seattle Children's Hospital
Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
Universitätsklinikum Hamburg-Eppendorf
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Re-MATCH
University of Florida
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
St. Jude Children's Research Hospital
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
ASCR
Washington University School of Medicine
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Wake Forest University Health Sciences
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor
Wake Forest University Health Sciences
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
National Cancer Institute (NCI)
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Case Comprehensive Cancer Center
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
National Institutes of Health Clinical Center (CC)
Study of Blood and Cheek Cell Samples From Patients With Glioma
University of California, San Francisco
Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors
Medical College of Wisconsin
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Stanford University
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Antineoplaston Therapy in Treating Patients With Brain Tumors
Burzynski Research Institute
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
Wake Forest University Health Sciences
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors
University Hospital, Montpellier
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial
Children's Oncology Group
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
CC-5013 in Treating Patients With Recurrent Glioma
National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
Duke University
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors
University of Pittsburgh
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
National Cancer Institute (NCI)
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors
Centre Hospitalier Universitaire Vaudois
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer
Barbara Ann Karmanos Cancer Institute
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
Duke University
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Duke University
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Magnetic Resonance Imaging in Determining Extent of Cancer in Patients With Newly Diagnosed Glioma
Jonsson Comprehensive Cancer Center
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Carmustine in Treating Patients With Recurrent Malignant Glioma
National Cancer Institute (NCI)